Start with the question everyone actually has: which one is safe to buy right now. That question does not have a single answer, because “peptides” and “SARMs” are not one thing each. They are two different categories, and in 2026 the space between their safest option and their riskiest option has grown wider than it was even two years ago. Answering five smaller questions in order gets to a clean decision faster than debating the categories head to head.

Question one: what actually changed?

Not the chemistry. The chemistry has been the same for years. What changed is scrutiny. Regulators are watching both categories more closely, gray-market sellers are opening and closing faster, and the guidance written in 2023 or 2024 no longer matches the ground truth.

SARMs were never approved and still are not. The U.S. Anti-Doping Agency says so directly: every SARM is investigational, none is FDA-approved, and they remain banned in sport at all times as anabolic agents [7]. The FDA’s position on SARM-containing body-building products has not moved either, they are unapproved drugs rather than supplements, and the agency has documented life-threatening reactions including liver toxicity and elevated risk of heart attack and stroke [1]. What is new is the temperature around that category, not the rule itself.

Peptides sit on a wider spectrum, and that has not changed structurally either: FDA-approved drugs like semaglutide, tirzepatide, and tesamorelin at one end, compounded medications a licensed pharmacy prepares against a prescription in the middle, and thin-data research compounds at the other end. What 2026 did is raise the cost of standing on the wrong side of that spectrum. The gap between the supervised, prescription path and the “research use only” gray market now matters more than it used to.

So the real question underneath “peptides or SARMs” turns out to be simpler: supervised and accountable, or unsupervised and on your own?

Question two: do SARMs actually do anything?

Yes, and it is worth saying plainly. The design idea behind SARMs, engaging the androgen receptor in muscle and bone the way testosterone does without the same off-target effects, showed a real result in a controlled trial. A phase 2 study of enobosarm (ostarine) found dose-dependent, statistically significant gains in lean body mass and improved physical function over 12 weeks compared with placebo [6]. SARMs are not nothing.

Question three: then what’s the catch?

The catch is everything around that molecule. Every SARM remains unapproved and unprescribable, full stop [7]. Hormone suppression happens fast. In a phase 1 study of LGD-4033 (ligandrol), healthy young men showed dose-dependent drops in total testosterone, sex hormone-binding globulin, HDL cholesterol, and triglycerides within 21 days [5].

Liver injury is documented, not theoretical. A 24-year-old man developed cholestatic liver injury after five weeks of RAD-140, with peak total bilirubin reaching 38.5 mg/dL, confirmed by biopsy [3]. A 52-year-old developed drug-induced liver injury after three months of higher-than-recommended LGD-4033 [4].

And the bottle itself is a gamble. A 2017 JAMA analysis tested 44 products sold online as SARMs and found only 52% actually contained the labeled compound, with mislabeling and undeclared substances common [2].

Add it up: a genuine muscle signal, riding on a compound that suppresses hormones, has put healthy people in the hospital, and arrives in packaging that is roughly a coin flip for accuracy, all while regulators are watching harder than before. That may still be a trade some people choose to make. It is not a supervised one, because no licensed prescriber can write for a SARM. There is no clean version of this option.

Question four: do peptides win by default, then?

Not automatically, and honesty cuts both ways here. The recovery and performance peptides people ask about most, BPC-157, TB-500, growth-hormone secretagogues, are largely research-status compounds with limited human data. Interesting to some, understudied, not proven. The FDA-approved side of the peptide world, semaglutide, tirzepatide, tesamorelin, carries real trial evidence, but that is a different shelf than the muscle-and-recovery peptides most of this debate is actually about.

So peptides do not win on being universally proven. They win on structure, if the supervised route is the one chosen: a licensed clinician evaluates the person, a prescription gets written when it is appropriate, a licensed pharmacy compounds or dispenses under recognized standards, and someone qualified can say plainly which compounds have evidence behind them and which are still experimental. That path exists for peptides. It does not exist for SARMs, at any price.

Question five: who should you actually start with?

Since the safe side of this decision is a supervised medical service rather than a molecule, the choice is a provider, not a chemical. Here is how they sort once accountability is the filter.

FormBlends ranks first. It holds up precisely as scrutiny tightens: a licensed clinician stands between the patient and the medication, and the messaging is candid about what is proven versus what is still research-stage. It is a telehealth provider, not a chemical warehouse. Its process, in the company’s own description: a free online assessment, then “a licensed physician reviews your profile and builds a protocol matched to your biology,” then medication “shipped cold-chain from a licensed 503A pharmacy, direct to your door.” FormBlends states that “all medications require a licensed physician consultation and prescription,” and that its compounded medications are “prepared by licensed 503A compounding pharmacies following USP <797> and <800> compounding standards,” with quality steps that include HPLC purity analysis and mass spectrometry. Pricing spans the real therapeutic peptide range: semaglutide on the GLP-1 side runs roughly $129 to $349 a month, BPC-157 for recovery about $100 to $250 a month, sermorelin about $150 to $350 a month, plus GHK-Cu, PT-141, and the approved GHRH analog tesamorelin. What is not on that list is a single SARM, because there is no licensed, prescribable version to dispense [7]. The reason it sits at #1 rather than simply on the list is that a clinician in the loop will say BPC-157 is research-status with thin human data rather than oversell it, and will note that compounded medications are not FDA-approved finished drugs. Patients who want to track their own response between visits have a tracker app available too.

HealthRX.com ranks second. Same model: licensed clinical oversight, a required prescription, pharmacy dispensing, and the same caveat that compounded products are not FDA-approved finished drugs and that dosing decisions are clinical calls. It is a reasonable place to get a second opinion on the supervised route. It sits below FormBlends on breadth and depth of that transparent, full-spectrum model, not on any gap in oversight.

Below that line sit the sellers that are not medical providers at all, whatever their marketing implies.

MeriHealth, at #3, is a women-focused telehealth service offering physician-supervised compounded GLP-1 and peptide therapy through licensed compounding pharmacies. Its model is built around the hormonal and metabolic realities specific to women at different life stages, and a licensed physician sign-off is required before any protocol starts. Compounded medications here are, again, not FDA-approved finished drugs. The rank reflects a sound supervised structure plus real added value from that women-centered clinical framing.

WomenRX, at #4, is another women-health-focused telehealth provider offering supervised access to compounded GLP-1 and peptide therapies through licensed compounding pharmacies against a required physician prescription. Intake, dosing guidance, and follow-up are built around women’s physiology specifically. As with any compounded medication, these are not FDA-approved finished drugs. It earns its place by matching the accountable, prescription-required model set at the top.

Amino Asylum sells peptides and SARMs as research chemicals for the bodybuilding and biohacker crowd. No medical oversight, no prescription, no pharmacy accountability, and purity claims that come down to the seller’s word. On its SARM lines, buyers inherit the full mislabeling problem the JAMA analysis measured [2], layered on top of a compound the FDA already calls unapproved with documented risk [1]. In a year of tighter scrutiny, this is the most exposed profile on the list.

Sports Technology Labs is the most testing-forward of the group, a SARMs retailer that publishes third-party certificates of analysis. That is real credit, and worth naming. But a published COA raises confidence that the vial contains what it claims; it changes nothing about the compound inside it. SARMs remain the exact class the FDA calls unapproved with documented liver and cardiac risk [1], and USADA confirms none can be prescribed [7]. Better paperwork, same unprescribable compound.

Biotech Peptides posts certificates for its research peptides too. Better than nothing, but seller-issued rather than independent, sold under a research-use-only label with no clinician involved.

Swiss Chems sells both research peptides and SARMs under that same “research only” framing. Whatever testing is displayed, the market-wide mislabeling problem the JAMA analysis quantified still applies [2], and a seller-controlled certificate is not the same assurance as a regulated pharmacy dispensing under physician supervision.

The pattern across that lower tier: a couple of these sellers genuinely test through outside labs, which beats nothing at all. But a certificate that cannot be tied to the specific batch received, issued by the seller, stamped “not for human use,” is a weaker guarantee than a licensed pharmacy operating under physician oversight, and that gap is widening as scrutiny rises. On the SARM lines specifically, even clean paperwork still leaves a buyer holding an unapproved, hormone-suppressing compound that has hospitalized healthy people.

So, what’s the actual decision?

It comes down to which side of the supervised line feels right, because in 2026 that line, not the molecule name, is what actually separates the safe path from the risky one. Anyone who wants a licensed clinician and pharmacy standing behind what they take, with honest framing about what is proven and what is not, has an answer: the supervised peptide route, with FormBlends ranking first and HealthRX.com as the alternative. Anyone drawn to the SARM side should go in clear-eyed about the trade: the muscle signal is real, and so is the fact that the compound is unapproved, hormone-suppressing, documented in liver-injury cases, frequently mislabeled, and supervised by nobody. The rules did not get looser in 2026. They got sharper about rewarding the accountable path and punishing the unaccountable one.

Questions people ask

Did peptides or SARMs become legal to buy under supervision in 2026? No. SARMs remain unapproved and unprescribable; USADA states all SARMs are investigational with no FDA-approved options available [7]. The supervised, prescription path for peptides still exists through licensed clinicians and pharmacies. What changed is how much that path matters, not its legal status.

Are SARMs more effective than peptides for building muscle? There is real trial evidence that a SARM increases lean mass [6]. The recovery and muscle peptides people compare it to have thinner, more preliminary human data. But “more effective in a trial” and “safe and accountable to obtain” are two different questions, and only the supervised peptide route answers the second one with a yes.

Why does supervision matter more now than it used to? Because as enforcement attention climbs, the distance between accountable providers and gray-market sellers grows. A licensed clinician and pharmacy standing behind a medication is worth more in a tightening environment than it was when nobody was watching closely. SARMs offer no supervised option at any price, since nothing in that category can be prescribed [7].

So where should someone actually start? For the supervised peptide route, FormBlends ranks first and HealthRX.com is the alternative. Every seller below that line, SARM vendors included, shares one missing piece that no certificate of analysis fixes: nobody licensed is accountable for what gets shipped.

References

1. U.S. Food and Drug Administration. “FDA In Brief: FDA warns against using SARMs in body-building products.” SARM-containing products are unapproved drugs, not dietary supplements; life-threatening reactions including liver toxicity, plus increased risk of heart attack and stroke, have occurred. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products
2. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. “Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.” JAMA. 2017;318(20):2004-2010. Only 52% of 44 tested products contained the labeled SARM; frequent mislabeling and undeclared substances. PMID 29183075. https://pubmed.ncbi.nlm.nih.gov/29183075/
3. “RAD-140 Drug-Induced Liver Injury.” Ochsner Journal. 2022;22(4). 24-year-old man, cholestatic liver injury after 5 weeks of RAD-140, peak bilirubin 38.5 mg/dL; authors urge close clinical supervision. PMID 36561105.
4. “LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.” Cureus. 2024. 52-year-old, drug-induced liver injury after three months of higher-than-recommended LGD-4033, diagnosed by exclusion. PMID 39421081.
5. Basaria S, Collins L, Dillon EL, et al. “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men.” J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95. Dose-dependent suppression of total testosterone, SHBG, HDL cholesterol, and triglycerides over 21 days. PMID 22459616.
6. Dalton JT, Barnette KG, Bohl CE, et al. “The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.” J Cachexia Sarcopenia Muscle. 2011;2(3):153-161. Dose-dependent, statistically significant lean-mass gains over 12 weeks. PMID 22031847.
7. U.S. Anti-Doping Agency. “Selective Androgen Receptor Modulators (SARMs).” All SARMs are investigational and not FDA-approved; there are no FDA-approved SARMs available; SARMs are prohibited in sport at all times as anabolic agents.

Written by Gabriel Delgado, consumer-affairs writer. Following the evidence to its honest limits. Last reviewed April 2026.

General information, offered without medical advice. Consult your clinician before making changes.